In BRAF inhibitor-resistant melanoma cells, a combination of MEK inhibitors with phosphatidylinositol 3-kinase (PI3K) or mechanistic target of rapamycin (mTOR) inhibitors can significantly decrease cancer cell survival [9,10]. Here, MTOR is linked to cancer.